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ABSTRACT Increased options for syringe acquisition and disposal have been associated
with reductions in high-risk behaviors. This study determined the extent of pharmacy
uptake in accessing syringes among injection drug users (IDUs) and estimated
associations between pharmacy uptake and safer injection/disposal practices. Two
years after the implementation of California’s Disease Prevention Demonstration
Project, which removed restrictions to non-prescription syringe sales through phar-
macies with local authorization, IDUs were recruited through street outreach in San
Francisco and interviewed regarding recent syringe acquisition, use, and disposal. The
sample of 105 persons included a high proportion of men (67%), people of color
(49%), and homeless persons (71%). The most common syringe source was a syringe
exchange program (SEP) (80%), with pharmacies being accessed by 39% of
respondents. The most commonly cited source of disposal was a SEP (65%), with very
few reports of pharmacy disposal (2%). Adjusted analysis showed that unsuccessful
attempts to purchase syringes at a pharmacy increased the odds of both injecting with a
used syringe and giving away a used syringe. Using a SEP decreased the odds of unsafe
injection and disposal practices. Thus, 2 years after the initiation of the California
Disease Prevention Demonstration Project, results from this small study suggest that
SEPs still provide the majority of syringe distribution and disposal services to San
Francisco IDUs; however, pharmacies now augment syringe access. In addition, unsafe
injection behavior is reported more often among those who do not use these syringe
sources. These results are consistent with prior studies in suggesting that increasing the
availability of syringes through SEPs and pharmacies, and developing bridges between
them, may further reduce syringe-related risk.
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INTRODUCTION
Injection drug use is a major risk factor for blood-borne pathogens, accounting for
one ﬁfth of human immunodeﬁciency virus (HIV) and the majority of hepatitis C
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534virus (HCV) infections in the USA.
1 Syringe exchange programs (SEPs) and
pharmacies are acknowledged in the ﬁelds of medicine and public health as the
two main sources of safe (i.e., sterile) syringes.
2–4 Disposal options that are widely
accepted as safe include SEPs, pharmacies, and specialized receptacle programs such
as syringe drop boxes.
5 Research indicates that increased access to sterile syringes
through SEPs results in reduced syringe sharing among injection drug users (IDUs)
6
and lower levels of HIV infection among individuals and communities.
7–9 Studies
regarding the impact of syringe acquisition through pharmacy sales are few. Those
conducted suggest the value of pharmacies in HIV prevention, as evidenced by lower
rates of HIV risk behaviors among IDUs who successfully use pharmacies to
purchase syringes,
10–12 the signiﬁcant contributions of pharmacists as HIV
prevention service providers,
13 and the importance of community-level education
regarding pharmacies as syringe resources.
14 Many state and local municipalities
throughout the USA have therefore amended laws by permitting the sale of non-
prescription syringes.
In addition to sterile syringe access, parallel public health concerns exist
regarding a lack of safe syringe disposal options, which have been associated with
publicly discarded syringes.
8 It is possible that non-prescription pharmacy syringe
sales may also reduce unsafe syringe disposal by virtue of onsite disposal facilities.
For instance, individuals’ safe syringe disposal increased over time following a 2001
New York demonstration program that allowed legal pharmacy sales of syringes
without prescriptions.
15 On the other hand, a study regarding pharmacy sales in
Minnesota found no changes in syringe disposal practices during the 1-year
following legal non-prescription pharmacy sales.
16 Whether differences in these
studies are due to geographic differences (e.g., attitudes or culture that are location-
speciﬁc) is unclear.
On January 1, 2005, California legislation (SB1159; the Disease Prevention
Demonstration Project (DPDP)) removed restrictions to the purchase of syringes
without a prescription in areas of local authorization (e.g., county or city). In
analysis of this policy change, Stopka et al. found broad disparities in the
authorization of over-the-counter syringe sales by both local health jurisdictions
and pharmacies throughout California; overall, a relatively small proportion of
pharmacies registered to participate, resulting in inconsistent implementation.
17 San
Francisco was one of 17 California Health Jurisdictions to enact the DPDP by
2007,
18 and it experienced one of the highest levels of participation by pharmacies
among approving jurisdictions, with 81% of surveyed pharmacists reporting
participation.
19 As part of a larger evaluation to assess the impact of the DPDP
implementation, the goal of the current study was to assess the uptake of pharmacies
as a source of syringe acquisition and disposal, as well as associations between
pharmacy uptake and HIV risk behaviors among a street-recruited sample of San
Francisco IDUs.
METHODS
A convenience sample of IDUs was recruited for this cross-sectional study by
outreach workers who were deployed to high drug-trafﬁc areas in San Francisco
during July 2007. The selection of recruitment locations was based on rates of drug
treatment entry; San Francisco zip codes with the highest per capita drug use were
chosen. Speciﬁc blocks of high drug activity, that were also considered safe for
outreach workers during daylight hours, were identiﬁed through discussions with
ACCESS TO STERILE SYRINGES THROUGH SAN FRANCISCO PHARMACIES 535outreach workers, service providers, researchers from the San Francisco General
Hospital Stimulant Treatment and Methadone Programs.
Recruitment
Study interviewers distributed HIV prevention literature and condoms to passersby,
indicating that a survey among IDUs was also being conducted. Persons expressing
interest in the survey were asked to step away from congregated individuals (to
increase privacy for the interview), conﬁrm eligibility (i.e., identiﬁcation proving that
the individual was at least 18 years of age and had visible scarring, or “track
marks,” from injection) and, after being informed of study procedures, provide
consent for study participation. Interviews were conducted in English; however, no
one was excluded from the study due to an inability to speak English. Personal
identiﬁers were not collected. The average duration of interviews was 15 min, and
individuals were reimbursed $5. This protocol was conducted with the approval of
the Committees on Human Research from the University of California, San
Francisco, California State University, Dominguez Hills, and the California Depart-
ment of Public Health.
Data Analysis
Outcome variables covered the prior 30 days and included obtaining a syringe from
a potentially unsafe source (i.e., a source other than a pharmacy or SEP), injecting
with a syringe that had been previously used by another person, giving a syringe that
the respondent had used to another person, and unsafe disposal of a used syringe
(i.e., trash, toilet, or a public place). Potential correlates of interest included
purchasing syringes at a pharmacy, as well as sociodemographic factors, self-
reported HIVand HCV infections, injection frequency, drug last injected, age at time
of ﬁrst injection, having concern about potential legal ramiﬁcations from carrying
syringes, obtaining syringes from a SEP, and reporting an unsuccessful attempt to
purchase syringes at a pharmacy. Data were collected before syringe disposal in the
municipal garbage system was made illegal by the State of California (SB 1305,
September 1, 2008) and before the installation of public syringe disposal boxes (San
Francisco Chronicle, Friday, August 3, 2007, Page A1).
Odds ratios (OR) and 95% conﬁdence intervals (CI) were used to determine the
magnitude of effect as well as the amount of variability in each estimate; inferences
were based on simultaneous adjustment for independent variables using multiple
logistic regression. Assuming an alpha of 0.05, the study had 80% power to see an
effect size of 0.27. The current study was considered exploratory; to avoid errors in
the interpretation of exploratory observational data, adjustment was not made for
multiple comparisons.
20
RESULTS
Recruitment efforts resulted in 105 individuals being interviewed during the month
of July 2007. Less than 2% of self-identiﬁed IDUs refused to participate. The sample
population was comprised of 51% Caucasian, 14% African American, 12% Latino
(a), and 18% “other” persons, while women comprised 33% of the sample
population (Table 1). Almost three quarters (71%) of respondents were homeless,
the median age was 42 years (interquartile range (IQR)=35–49), and the median age
at ﬁrst injection was 17 years (IQR=14–26). The median number of injections was
ﬁve during the prior week (IQR=2–20); the most common drugs last injected were
RILEY ET AL. 536heroin (51%) and methamphetamine/speed (35%). HIV infection was self-reported
by 17% of respondents, while 64% self-reported HCV infection.
Syringe Sources
The most common sources of syringes in this population were a SEP (80%),
friend (46%), pharmacy (39%), “on the street” (37%), drug dealer (7%), and
diabetic (3%). Among those who obtained syringes at a pharmacy, 24% reported
obtaining at least half of all syringes used during the prior 30 days there. By
comparison, 89% of participants who obtained syringes at a SEP obtained at
least half of all syringes there. The only signiﬁcant correlate of obtaining syringes
from an unsafe source (non-SEP and non-pharmacy) was homelessness (OR=
2.95, CI=1.19–7.33; Table 1).
Twelve individuals (11%) reported injecting with a syringe during the past
30 days that had been previously used by another person. After adjusting for white/
Caucasian race (adjusted OR (AOR)=5.23, CI=1.08–25.21), reporting a failed
attempt to purchase syringes at a pharmacy increased the odds of injecting with a
used syringe (AOR=12.00, 95% CI=2.79–51.66), while obtaining syringes at a SEP
decreased the odds of injecting with a used syringe (AOR=0.18, 95% CI=0.03–
0.75; Table 1).
Syringe Disposal
The most common sources of syringe disposal in this population were an SEP
(65%), trash (41%), ﬂushed down the toilet (12%), gave away (9%), pharmacy
(2%), and left in a public place (1%). Among those who disposed of syringes at
an SEP, 82% reported disposing at least half of all syringes used during the prior
30 days there.
Seven individuals (7%) reported giving away their used syringes. Adjusted
analysis showed that reporting a failed attempt to purchase syringes at a pharmacy
increased the odds of giving away a used syringe (AOR=9.32, 95% CI=1.73–
50.19), while obtaining syringes at an SEP decreased the odds of giving away a used
syringe (AOR=0.15, 95% CI=0.03–0.75; Table 1).
Fifty individuals (48%) reported unsafe disposal of their syringes (i.e., trash,
toilet, or public place) during the past 30 days. In adjusted analysis, obtaining
syringes from a SEP decreased the odds of unsafe disposal (AOR=0.17, CI=0.05–
0.95), and being homeless increased the odds of unsafe syringe disposal (AOR=
3.75, CI=1.41–9.55; Table 1).
DISCUSSION
Two years after the implementation of California’s DPDP, and in a city where 81%
of pharmacists report selling syringes without a prescription,
19 results from this
small study suggest that SEPs still provide the majority of syringe distribution and
disposal services to San Francisco IDUs. However, 39% of IDUs who participated in
this study now also access sterile syringes from pharmacies in a jurisdiction where
both sources are available. After adjusting for SEP use, unsuccessful attempts to
purchase syringes at a pharmacy were signiﬁcantly associated with using and giving
away previously used needles. These data suggest public health beneﬁts from
reducing barriers to syringe access at pharmacies.
The association between an inability to obtain syringes from a pharmacy and
giving away used syringes is noteworthy. Whether this association is confounded or
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RILEY ET AL. 538mediated by an unmeasured factor, or whether it is indeed a true effect, is currently
unclear. While the current study is unable to determine the mechanism through
which barriers to pharmacy-sold syringes would inﬂuence giving away used
syringes, several possibilities exist. For instance, an inability to purchase syringes
at a pharmacy may be correlated with an inability to dispose. If the closest pharmacy
to which an individual lives does not dispose of syringes, s/he may have more
syringes on hand to lend. Additionally, if the closest pharmacy to which an
individual lives does not sell syringes, s/he may keep the few owned in her/his
possession, making these syringes more accessible and thus more likely to be
loaned.
Due to the cross-sectional nature of the current study, results presented herein
cannot be directly compared to several longitudinal studies regarding the impact of
syringe access through pharmacies on IDU risk behavior. However, given that an
inability to access syringes through a pharmacy was correlated with using and giving
away previously used syringes, these results are consistent with the longitudinal
evidence to date, indicating that increased options for syringe access predict lower
risk behaviors. For instance, Cleland et al. found that safe syringe disposal increased
following New York’s expanded syringe demonstration program;
15 Singer et al.
reported that pharmacies were an important source of sterile syringes 4 years after
policy changes that allowed sales in Connecticut,
21 and results reported by Des
Jarlais et al. suggested that a comprehensive public health approach, using multiple
strategies across systems, could enhance the prevention of blood-borne pathogens.
22
Taken together, these studies suggest that pharmacies can be an effective and
sustainable mode of reducing injection-related HIV risk by augmenting syringe
access established at programs such as SEPs.
Potential discrepancies within and between studies regarding pharmacy access
to syringes should be noted. First, an unsuccessful attempt to purchase syringes
through a pharmacy was a signiﬁcant correlate of high-risk behavior in the current
study; however, successfully purchasing a syringe through a pharmacy was not a
protective factor. This suggests differences between persons who are able and those
who are unable to purchase syringes at a pharmacy, and emphasizes a need to focus
prevention efforts on persons who are unable to access resources. Given the cross-
sectional nature of the current study, it is possible that persons who unsuccessfully
attempted to purchase syringes at a pharmacy may have had higher baseline risk
proﬁles, not that unsuccessful attempts to purchase a syringe prompted high-risk
behavior. In addition, given the nature of the available data, an inability to purchase
syringes may have stemmed from unusual purchasing times/locations
12 or an
inability to pay rather than reluctance on the part of the pharmacists. However,
using the example of giving away used syringes, variables that have been tradition-
ally associated with baseline risk behavior, such as injection frequency, income, and
age, were not strong correlates. Thus, the results suggest that barriers to accessing
syringes through a pharmacy may have potential detrimental effects on the risk
behavior of IDUs. In addition, even though Cotton-Oldenburg et al. reported
increases in pharmacy use and decreases in syringe sharing following changes in
Minnesota legislation that permitted non-prescription syringe sales,
16 there were no
reported differences in safe syringe disposal. The current study also found no
signiﬁcant association between purchasing syringes at a pharmacy and safe syringe
disposal, which is inconsistent with results from New York City. Whether differences
are due to study design or geographical differences in legislation implementation or
IDU behavior are unclear. Legislation is often passed more quickly than research
ACCESS TO STERILE SYRINGES THROUGH SAN FRANCISCO PHARMACIES 539funding can be obtained to evaluate it; however, future individual-level longitudinal
data collected before and after policy change would provide important data to
address these potential differences. While a better understanding of the differences
within and between studies is needed, as well as a more detailed understanding of
how and why the studies presented herein inﬂuenced IDU risk behavior, each study
cited has found signiﬁcant associations between non-prescription syringe access and
decreases in injection-related risk behavior, consistently indicating a role for
pharmacies in the reduction of blood-borne pathogens.
These results, in combination with others cited herein, have implications for
further reductions in syringe-related risk that may be possible in the context of legal
syringe access through pharmacies. First, increasing the number of pharmacies that
sell syringes without a prescription may decrease the number of persons who
unsuccessfully attempt to purchase syringes at a pharmacy. In addition, as reported
in New York, an increase in the use of pharmacies over time would be expected
among IDUs who have not yet accessed them.
23 Increased availability through
pharmacies and increased uptake by IDUs could decrease the risk of injecting with a
used syringe and giving away used syringes. Second, efforts to develop more
accessible systems of accepting and disposing used syringes at pharmacies, and
efforts to encourage IDUs to dispose of used syringes at pharmacies, may increase
pharmacy-based syringe disposal. Third, developing bridges between pharmacies
and SEPs would increase options for safe acquisition and disposal. In this
environment, educating SEP staff and IDUs about pharmacy options and locations,
as well as educating pharmacists about SEP options and locations, would be
important. The education and coordinated efforts of pharmacists, health care
providers, and public health practitioners to improve access to sterile syringes
through pharmacy sales is a long-standing goal
24,25 that has been substantiated by
more recent ﬁndings
19 as well as the current study.
While this study’s strengths lie in its community-based approach, some
limitations should be considered. Even though interviewers did not collect
identifying information, data were self-reported, thus socially desirable responding
as well as recall bias were possible. However, no evidence exists to suggest that
either response or recall bias would differ by persons who do or do not use
pharmacies or SEPs. Data were also cross-sectional, making it impossible to
establish incidence or change over time. Additionally, the small number of
respondents resulted in wide CIs for some associations. Finally, in the context of
California’s current implementation of expanded syringe access, these results may
only be representative of California Jurisdictions with the highest levels of syringe
access. This is because the county of San Francisco enacted the DPDP, and the
proportion of participating pharmacies was high (81%) relative to other approving
California Local Health Jurisdictions.
19 In this environment, accepting and giving
away used syringes were more likely among individuals who had unsuccessfully
tried to purchase syringes at a pharmacy.
In an environment where SEPs are available, pharmacy syringe sales are legal,
and a high proportion of pharmacies register to sell syringes; over one third of IDUs
draw on both syringe sources, and measures of success in accessing each are
associated with safe syringe-related behavior, while few IDUs utilize pharmacies for
disposal. This and earlier studies suggest that increasing the number of options for
syringe access and disposal in other California Local Health Jurisdictions would
facilitate lower risk behaviors, thereby decreasing the risk of infections with blood-
borne pathogens.
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